
Pfizer and Allergan Terminate Merger Agreement
The companies announced that they have mutually decided to terminate the planned merger after the US Department of Treasury and the IRS issue temporary and proposed regulations on tax inversion.
Pfizer and Allergan announced on April 6, 2016 that their planned merger agreement has been mutually terminated. Pfizer will pay Allergan $150 million for reimbursement of expenses associated with the transaction.
The termination of the merger is a result of the US Department of Treasury and the Internal Revenue Service’s (IRS) April 4, 2016 announcement issuing temporary and proposed regulations to limit the “benefits of and limit the number of corporate tax inversions.” The Treasury said it will focus on companies that have engaged in a number of acquisitions in a series, and it plans to limit foreign companies benefits in inversion.
The Pfizer and Allergan merger termination was driven by the Treasury announcement, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement, Pfizer said in a
“We plan to make a decision about whether to pursue a potential separation of our innovative and established businesses by no later than the end of 2016, consistent with our original timeframe for the decision prior to the announcement of the potential Allergan transaction,” Pfizer CEO Ian Read said in a statement. “As always, we remain committed to enhancing shareholder value.”
Pfizer and Allergan
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.